# Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

> **NCT01471782** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen Research (Munich) GmbH** · enrollment: 93 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** Blinatumomab

## Key facts

- **NCT ID:** NCT01471782
- **Lead sponsor:** Amgen Research (Munich) GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2014-08
- **Final completion:** 2016-05
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2017-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01471782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01471782, "Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01471782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*